Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LYS006 · 1 trial · 1 indication
Inflammatory facial lesion count included papules, pustules, and nodules. The natural log transformed inflammatory facial lesion count up to Week 12 was analyzed using a Bayesian mixed effect model for repeated measurements (MMRM). Values estimated from the model at Week 12 are presented in the table. Posterior geometric mean and 90% credible intervals in each group are presented.
| Arm | Type | Description |
|---|---|---|
| LYS006 20 mg BID | EXPERIMENTAL | LYS006, 20 mg, orally, twice daily (BID), for 12 weeks |
| LYS006 2 mg BID | EXPERIMENTAL | LYS006, 2 mg, orally, BID, for 12 weeks |
| Placebo BID | PLACEBO_COMPARATOR | Matching placebo, orally, BID, for 12 weeks |
| Name | Type | Description |
|---|---|---|
| LYS006 20 mg | DRUG | LYS006 20 mg, capsules, oral administration, BID, for 12 weeks |
| LYS006 2 mg | DRUG | LYS006 2 mg, capsules, oral administration, BID, for 12 weeks |
| Placebo | DRUG | Matching placebo, capsules, oral administration, BID, for 12 weeks |
Inclusion criteria: * Male and female subjects aged 18 to 45 years of age inclusive, and otherwise in good health as determined by medical history, physical examination, vital signs, ECGs and laboratory tests at screening. * Body weight between 50 and 120 kg, both inclusive, at screening. * Patient...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | Ziltivekimab |
| AstraZeneca PLC | AZN | 1 | - | Undisclosed |
LYS006 is an investigational small molecule being developed for the treatment of moderate to severe inflammatory acne. It is a dermatology therapy that has been studied in a Phase 2 clinical trial to assess its efficacy and safety in patients with this condition.
LYS006 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company has conducted clinical research to evaluate the drug's potential in treating inflammatory acne.
LYS006 is in Phase 2 clinical development. It has completed a Phase 2 trial that evaluated its efficacy and safety in patients with moderate to severe inflammatory acne. The drug is investigational and has not been approved by regulatory authorities.
LYS006 has been studied in one completed Phase 2 clinical trial, identified as NCT03497897. This randomized, double-blind, placebo-controlled study enrolled 66 participants with moderate to severe inflammatory acne across the United States, Czechia, France, Germany, Hungary, and the Netherlands.
No alternative names for LYS006 have been disclosed in the available clinical trial information. The drug is identified solely by its investigational code name LYS006 in the completed Phase 2 study for inflammatory acne.